Corneal laser-strengthening to reduce new blood vessels in the eye
Part of Eyes & vision clinical trials.
This trial studies corneal crosslinking to treat active inflammation or infection that leads to new blood vessels growing into the cornea. It may help reduce ongoing damage and lower the risk of problems, including issues that can threaten a future corneal transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have active inflammation or infection causing blood vessels to grow into your cornea
- You may also qualify if the vessels keep growing even after steroid eye drops
- You must be willing and able to sign informed consent
- You do not have a known allergy or sensitivity to the study treatment medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two ways to strengthen the cornea (the clear front surface of your eye) in people with keratoconus or corneal weakening after laser vision surgery. It may help determine whether an accelerated (faster) approach works as well and with acceptable safety.
This study tests a lab-grown (ex vivo) method of strengthening donor cornea tissue used in cornea transplants for people with keratoconus. It may help improve how well the transplanted cornea heals and functions.
This study tests a same-day procedure that strengthens the cornea (the clear front part of the eye) in both eyes using a special light treatment, called cross-linking. It may help slow or stop the progression of keratoconus, a condition where the cornea becomes cone-shaped and causes blurry vision.
This early-phase study tests a riboflavin “cross-linking” treatment to slow or stop corneal thinning in conditions like keratoconus or related cornea bulging. It’s meant to help stabilize corneal shape and thickness to protect vision.
This trial studies whether pretreatment with a specific vitamin and ultraviolet light can help a future, high-risk corneal transplant keep its new cornea healthy for longer. It may help people whose corneas already have new blood vessels, which can make transplant results harder.
This trial tests a combination of two treatments—a heat procedure and a medication injection—to reduce abnormal blood vessel growth on the clear front surface of your eye (cornea). The goal is to improve your vision and prevent further damage.
Hear when a new Corneal Neovascularization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.